Genta submits new data to Genasense NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genta's major amendment to its Genasense (oblimersen) NDA for chronic lymphocytic leukemia will extend the user fee goal by 90 days to Jan. 29, Genta said Oct. 30. New analyses "reinforce" the conclusion that Genasense increased durable complete remissions, the company said. Genta is working to counter an FDA advisory committee rejection of Genasense in September due to lack of evidence of clinical benefit...
You may also be interested in...
Genta starts Genasense melanoma combination study
Genta has initiated a new clinical study to evaluate its Bcl-2 inhibitor Genasense (oblimersen) in patients with advanced melanoma, the company announces Nov. 29. The trial is the first follow-on study to Genta's Phase III advanced melanoma trial of Genasense plus dacarbazine. The new pilot study will evaluate safety, efficacy and pharmacokinetics of Genasense combined with Abraxis BioScience's Abraxane (paclitaxel protein-bound particles) and Schering-Plough's Temodar (temozolomide). Meanwhile, Genta saw a setback Dec. 8 when preliminary results of a Phase III study of Genasense in acute myeloid leukemia failed to reach the overall survival primary endpoint. The company's NDA for chronic lymphocytic leukemia has a user fee date of Jan. 29 (1Pharmaceutical Approvals Monthly November 2006, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.